---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000074"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:25:01.844735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo

## Summary
- As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.
- Partial responses in 62% of evaluable: 80% (8/10) squamous NSCLC, 46% (5/11) non-squamous.
- No dose-limiting toxicities; only one TRAE leading to drug discontinuation; low-grade irAEs.
- ImmuneOnco expects to present full data at a future medical conference.

## SEC filing metadata
- accession: 0001789769-25-000074
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/0001789769-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/til-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000074
- JSON: https://secwatch.observer/filing/0001789769-25-000074.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.